Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (NCT06712355)

🧪 Interventions in This Study

• Pumitamig (DRUG)
• Atezolizumab (DRUG)
• Etoposide (DRUG)
• Carboplatin (or cisplatin if carboplatin is not tolerated) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (221 Sites)

Showing the first 25 of 221 sites.

• ACRC Arizona Clinical Research Center — Tucson, Arizona
• Clermont Oncology Center — Clermont, Florida
• Cancer Care Centers of Brevard, Inc — Palm Bay, Florida
• Northside Hospital Atlanta — Atlanta, Georgia
• Illinois Cancer Specialists — Niles, Illinois
• Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
• McFarland Clinic — Ames, Iowa
• Helen G. Nassif Community Cancer Center — Cedar Rapids, Iowa
• Baptist Health Hardin Cancer Center — Elizabethtown, Kentucky
• LSU Health Baton Rouge - North Clinic — Baton Rouge, Louisiana
• Our Lady of the Lake Hospital, Inc. — Baton Rouge, Louisiana
• Frederick Health Hospital- James M Stockman Cancer Institute — Frederick, Maryland
• Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center — Burlington, Massachusetts
• Baptist Cancer Center — Southaven, Mississippi
• Washington University School of Medicine — St Louis, Missouri
• Nebraska Hematology-Oncology (NHO) — Lincoln, Nebraska
• Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center — New York, New York
• White Plains Hospital — White Plains, New York
• Cleveland Clinic - Akron General Hematology & Oncology — Akron, Ohio
• Cleveland Clinic Mercy Hospital Cancer Center — Canton, Ohio
• The Christ Hospital Cancer Center — Cincinnati, Ohio
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion — Cleveland, Ohio
• Cleveland Clinic Foundation — Cleveland, Ohio
• Kettering Medical Center — Kettering, Ohio

📞 Contact the Study Coordinator

Phone: (496) 131-9084

Email: patients@biontech.de

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive-stage Small-cell Lung Cancer

• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Springdale, Arkansas
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Mobile, Alabama
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy — Anchorage, Alaska
• MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer — Washington D.C., District of Columbia
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — Los Angeles, California

Explore by condition: All Extensive-stage Small-cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.